Brief: Avalon Globocare Provides Updates On Its Lead Scientific And Clinical Programs In Car T-Cell Therapy And Covid-19

Change Agents

13/07/2020 14:13

July 13 (Reuters) - Avalon Globocare Corp  AVCO.O :
    * AVALON GLOBOCARE PROVIDES UPDATES ON ITS LEAD SCIENTIFIC
AND
CLINICAL PROGRAMS IN CAR T-CELL THERAPY AND COVID-19
    * AVALON GLOBOCARE CORP - SUCCESSFULLY COMPLETED
PRE-CLINICAL
RESEARCH ON AVA-011, INCLUDING TUMOR CYTOTOXICITY STUDIES
    * AVALON GLOBOCARE CORP - ACHIEVED 90% CR RATE WITH MINIMUM
TOXICITY/ADVERSE SIDE EFFECTS IN PHASE I STUDY OF 4-1BB BASED
ANTI-CD19 CAR-T THERAPY
    * AVALON GLOBOCARE CORP - EXPECT TO LAUNCH FIRST-IN-HUMAN
TRIAL OF
AVA-011 IN Q1 2021

Source text for Eikon:  ID:nGNX17w6wB 
Further company coverage:  AVCO.O 

 (Reuters.Briefs@thomsonreuters.com)